Company Monitoring Page for Amarin

latest headlines for company on cafepharma

Vascepa sparkle set to light up Amarin's fourth quarter revenue
Endpoints
Tue, 01/7/20 - 10:31 am
Tags:
Amarin, Vascepa, earnings
Amarin stock heads toward highest prices in more than a decade after new Vascepa FDA approval
Yahoo/Marketwatch
Sun, 12/15/19 - 11:20 pm
Tags:
Amarin, Vascepa, FDA
Amarin eyes blockbuster Vascepa sales as FDA grants heart-helping label expansion
Fierce Pharma
Fri, 12/13/19 - 09:36 pm
Tags:
Amarin, Vascepa, FDA, Cardiovascular
2 Top Biotech Buyout Candidates
Motley Fool
Wed, 12/11/19 - 10:38 am
Tags:
M&A, Amarin, Vascepa, Aurinia Pharmaceuticals, voclosporin
4 FDA Dates Biotech Investors Should Circle in December
Motley Fool
Sun, 12/8/19 - 10:24 pm
Tags:
FDA, Amgen, anti-inflammatories, ABP710, Bausch Health Companies, acne, IDP-123, Intra-Cellular Therapies, lumateperone, schizophrenia, Vascepa, Amarin
Go or no go? Vascepa’s finale and Allergan's pain relief
EP Vantage
Mon, 12/2/19 - 10:37 am
Tags:
FDA, Amarin, Vascepa, Allergan, migraines, ubrogepant
Before 2019 closes, the FDA has 3 key approval decisions to make
Biopharma Dive
Wed, 11/27/19 - 12:43 pm
Tags:
Allergan, ubrogepant, migraines, Amarin, Vascepa, Intra-Cellular Therapeutics, lumateperone, schizophrenia, bipolar disorder, drug approvals, FDA
Amarin for $20B? Novartis' MedCo deal drives fresh buyout rumors for Vascepa's maker
Fierce Pharma
Mon, 11/25/19 - 09:49 pm
Tags:
Amarin, M&A, Novartis, Medicines Company, Gilead Sciences
Does Amarin Have a Dark Horse Suitor?
Motley Fool
Sun, 11/24/19 - 11:32 pm
Tags:
Amarin, Vascepa, M&A, Gilead Sciences
Looking for a Biotech Stock That's an Ideal Buyout Candidate? This Is It.
Motley Fool
Wed, 11/20/19 - 10:02 am
Tags:
Amarin, Vascepa, M&A, Amgen, Novartis, Pfizer
Acasti plays catch-up to Amarin’s Vascepa
EP Vantage
Wed, 11/20/19 - 09:56 am
Tags:
Ascati, Amarin, Vascepa, CaPre
AHA: Amarin's Vascepa halts progression of arterial plaque in key study
Fierce Pharma
Mon, 11/18/19 - 09:54 am
Tags:
Amarin, Vascepa, AHA, FDA, aterial plaque
What's next for Amarin? CEO John Thero talks Vascepa's label, pricing and future partnerships
Biopharma Dive
Sat, 11/16/19 - 10:35 pm
Tags:
Amarin, Vascepa, John Thero, labeling
What's Next for Amarin's Stock?
Motley Fool
Fri, 11/15/19 - 10:41 am
Tags:
Amarin, Vascepa, FDA, pharma stocks, advisory panels
FDA Advisory Committee Votes Unanimously in Favor of Expanding Amarin’s Vascepa Label
RAPS.org
Thu, 11/14/19 - 07:45 pm
Tags:
FDA, advisory panel, Amarin, Vascepa
Shares of Amarin rise on favorable opinion from FDA committee
Marketwatch
Tue, 11/12/19 - 10:10 am
Tags:
FDA, Amarin, Vascepa
Amarin (AMRN) Beats Earnings & Revenues Estimates in Q3
Zacks.com
Tue, 11/5/19 - 11:54 pm
Tags:
Amarin, earnings
The future of Vascepa sales, and Amarin, could hinge on next week's panel
EP Vantage
Tue, 11/5/19 - 10:28 am
Tags:
Amarin, Vascepa, FDA, advisory panels, M&A
J&J's Xarelto, Amarin's Vascepa are cost-effective, not budget friendly — ICER
Endpoints
Fri, 10/18/19 - 10:18 am
Tags:
ICER, drug pricing, JNJ, Xarelto, Amarin, Vascepa
Why Amarin Investors Have Their Eyes on Nov. 14
Motley Fool
Sun, 10/13/19 - 11:41 pm
Tags:
Amarin, Vascepa, FDA

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.